Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) is a rat-derived anti-LPAM-1/Integrin α4β7 IgG2a, κ type antibody inhibitor. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) specifically reacts with both chains of the α4β7 heterodimer and blocks the adhesion to immobilized mucosal addressin cell adhesion molecule-1 ( MAdCAM-1 ). Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) suppresses the proliferation and cytokine secretion of CD8+ T cells. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) decreases Peyer’s patches and follicular B cells in mice. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) can be used for the researches of inflammation, such as ulcerative colitis [1] [2] [3] [4].
In Vivo, Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) (2 μg per 106 cells, at least 30 minutes before injecting) reduces homing of HPCs (hematopoietic progenitor cells) to bone marrow in E-selectin–deficient (E-/-) mice models[1]. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) (500 μg, i.p., daily from day 8 to 10) does not cause aberrant pregnancies in allogeneic BALB/c x C57BL/6J pregnancies[2]. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) (i.p., a single dose) decreases Peyer’s patches and follicular B cells in C56B6 WT mice[4].
In Vitro, Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) (10 μg/mL, 10 mins) blocks the adhesion of FDCP-mix cells to immobilized mucosal addressin cell adhesion molecule-1 (MAdCAM-1)[1]. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) (100 μg/mL, 72 h) suppresses the proliferation and cytokine secretion of CD8+ T cells[3].
References:
[1]. Katayama Y, et al. Integrin alpha4beta7 and its counterreceptor MAdCAM-1 contribute to hematopoietic progenitor recruitment into bone marrow following transplantation. Blood. 2004 Oct 1;104(7):2020-6.
[2]. Fernekorn U, et al. Functional involvement of P-selectin and MAdCAM-1 in the recruitment of alpha4beta7-integrin-expressing monocyte-like cells to the pregnant mouse uterus. Eur J Immunol. 2004 Dec;34(12):3423-33.
[3]. Su Z, Bian L, et al. Gut-tropic α4β7+CD8+ T cells contribute to pancreatic β cell destruction in type 1 diabetes. Front Immunol. 2025 Jul 10;16:1623428.
[4]. P Canales-Herrerias, et al. P061 Response to anti-α4β7 therapy in Ulcerative colitis is associated with lymphoid aggregate attrition through impaired recruitment of naïve lymphocytes, Journal of Crohn's and Colitis, Volume 17, Issue Supplement_1, February 2023, Pages i227–i228.
In Vivo, Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) (2 μg per 106 cells, at least 30 minutes before injecting) reduces homing of HPCs (hematopoietic progenitor cells) to bone marrow in E-selectin–deficient (E-/-) mice models[1]. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) (500 μg, i.p., daily from day 8 to 10) does not cause aberrant pregnancies in allogeneic BALB/c x C57BL/6J pregnancies[2]. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) (i.p., a single dose) decreases Peyer’s patches and follicular B cells in C56B6 WT mice[4].
In Vitro, Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) (10 μg/mL, 10 mins) blocks the adhesion of FDCP-mix cells to immobilized mucosal addressin cell adhesion molecule-1 (MAdCAM-1)[1]. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) (100 μg/mL, 72 h) suppresses the proliferation and cytokine secretion of CD8+ T cells[3].
References:
[1]. Katayama Y, et al. Integrin alpha4beta7 and its counterreceptor MAdCAM-1 contribute to hematopoietic progenitor recruitment into bone marrow following transplantation. Blood. 2004 Oct 1;104(7):2020-6.
[2]. Fernekorn U, et al. Functional involvement of P-selectin and MAdCAM-1 in the recruitment of alpha4beta7-integrin-expressing monocyte-like cells to the pregnant mouse uterus. Eur J Immunol. 2004 Dec;34(12):3423-33.
[3]. Su Z, Bian L, et al. Gut-tropic α4β7+CD8+ T cells contribute to pancreatic β cell destruction in type 1 diabetes. Front Immunol. 2025 Jul 10;16:1623428.
[4]. P Canales-Herrerias, et al. P061 Response to anti-α4β7 therapy in Ulcerative colitis is associated with lymphoid aggregate attrition through impaired recruitment of naïve lymphocytes, Journal of Crohn's and Colitis, Volume 17, Issue Supplement_1, February 2023, Pages i227–i228.